SRPT

Sarepta Therapeutics' stock price has experienced significant volatility in the past six months. In Q1 2026, the company reported revenues of $731 million and adjusted EPS of $3.16, exceeding expectations, but Elevidys sales were down due to label restrictions, leading to a share price drop. The CEO's retirement announcement raised leadership uncertainty. Positive early siRNA data lifted shares in March 2026. Sarepta submitted sNDAs to the FDA for AMONDYS 45 and VYONDYS 53. While shares rebounded approximately 16.5% over the month leading up to April 24, 2026, they carried a steep ~65% loss over the past year.